We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Blood Test Detects Chronic Traumatic Encephalopathy During Life

By LabMedica International staff writers
Posted on 22 Mar 2016
Image: The NanoSight LM10 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
Image: The NanoSight LM10 instrument provides an easy-to-use, reproducible platform for nanoparticle characterization (Photo courtesy of Malvern Instruments).
Chronic traumatic encephalopathy (CTE) is a tauopathy associated with prior exposure to repetitive head impacts, such as those incurred through American football and other collision sports and diagnosis is made through neuropathological examination.

A method has been developed for measuring plasma exosomal tau. Exosomes are very small vesicles that are released from all types of cells throughout the body, including brain cells. They can be isolated in all body fluids, including plasma, a component of blood.

Scientists at Boston University School of Medicine (MA, USA) and their colleagues examined 78 former National Football League (NFL) players and a control group of 17 former non-contact sport athletes. Extracellular vesicles were isolated from plasma. Fluorescent nanoparticle tracking analysis was used to determine the number of vesicles staining positive for tau. Blood was drawn by venipuncture and immediately processed. Plasma samples were stored in 0.75 mL tubes at -80 °C, packed in dry ice, and shipped overnight in one batch to the Exosome Sciences laboratory (Monmouth Junction, NJ, USA).

Extracellular vesicles were isolated from the plasma samples by size exclusion chromatography. Plasma samples were applied to the column and it was then run isocratically. The elution was monitored at 280 nm and the void volume material (exosome fraction) was collected and pooled. The size profiles and concentrations of the chromatographically isolated exosomes were performed using the Nanosight LM10 instrument (Malvern Instruments Ltd.; Malvern, UK) equipped with a 405 nm laser, a scientific complementary metal-oxide-semiconductor (sCMOS) camera and Nanoparticle Tracking Analysis (NTA) software.

The method of measuring plasma exosomal tau is referred to as a TauSome. The groups did not differ in total plasma exosomes, but the NFL group had significantly higher plasma exosomal tau than the control group. The C-statistic is maximized when the plasma exosomal tau level is set to 0. Using 0 as a threshold resulted in 82% sensitivity, 100% specificity, 100% positive predictive value and 53% negative predictive value. The number of tau-positive plasma exosomes was significantly correlated with performance on standardized tests of memory and psychomotor speed; the higher the TauSome level, the worse the performance.

Jim Joyce, Founder of Exosome Sciences and Chairman and CEO of Aethlon Medical (San Diego, CA, USA), said, “We are extremely pleased that our initial study data has been published and we appreciate forthcoming opportunities to further advance our TauSome biomarker as a noninvasive solution to detect and monitor CTE in living individuals.” The study was published on February 10, 2016, in the Journal of Alzheimer's Disease.

Related Links:

Boston University School of Medicine
Exosome Sciences
Malvern Instruments Ltd.


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Rapid Sepsis Test
SeptiCyte RAPID

Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
PURITAN MEDICAL